Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05448274
Other study ID # H-21075670
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 3, 2023
Est. completion date September 14, 2023

Study information

Verified date September 2023
Source University Hospital, Gentofte, Copenhagen
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A randomized, placebo controlled crossover study investigating the potential metabolic effects of the naturally occurring gut microbe Ruminococcus torques in healthy, overweight adults.


Description:

By analyzing blood samples, indirect calorimetric as well as thermographic assessment of clavicular temperature we want to investigate whether or not the commensal gut bacterium Ruminococcus toqrues strain ATCC 27756 has any metabolic effects in healthy adults. The subjects will recieve the intervention with the live bacterium given through a duodenal feeding tube. The trial is double blinded and placebo controlled using a crossover design. Subjects will be given an intervention with either placebo or Ruminococcus on two different study days with up to six weeks of wash-out between each study day.


Recruitment information / eligibility

Status Completed
Enrollment 32
Est. completion date September 14, 2023
Est. primary completion date September 6, 2023
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 40 Years
Eligibility Inclusion Criteria: - Age between 18 and 40 years - Self-reported good health - Caucasian - Body Mass Index > 27 kg/m^2 Exclusion Criteria: - Any known disorder/disease that could interfere with study results or is seen as compromising to the study (as assessed by the investigator), for example diabetes, cancer or cardiovascular or kidney disease. - Use of any daily medication as well as p.r.n. (pro re nata; not taken regularly) medication that cannot be discontinued during the trial - Use of antibiotics during the recent three months - Acute or chronic gastrointestinal symptoms - Lactose intolerance - Pregnancy - ongoing or planned - Smoking - Alcohol or drug abuse - Use of creatine as dietary supplement during study period - Plasma creatinine above the normal range (>105 µmol/L for men and >90 µmol/L for women) - Known significant liver disease or plasma alanine transaminase concentration = 3 × normal value - Values for hemoglobin, leukocytes, or thrombocytes outside of the normal ranges

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Placebo
The placebo will consist of solely glycerol-phosphate-buffered isotonic saline.
Ruminococcus torques
10^11 live bacterial cells in glycerol-phosphate-buffered isotonic saline

Locations

Country Name City State
Denmark Gentofte Hospital Hellerup

Sponsors (4)

Lead Sponsor Collaborator
Oluf Pedersen Technical University of Denmark, University Hospital, Gentofte, Copenhagen, University of Copenhagen

Country where clinical trial is conducted

Denmark, 

Outcome

Type Measure Description Time frame Safety issue
Other Heart rate Changes in heart rate during study day During the six hours of the study day (up to six weeks between study days)
Other Blood pressure Changes in blood pressure during study day During the six hours of the study day (up to six weeks between study days)
Other Various hormones related to metabolism Differences in measures of various hormones during the study day During the six hours of the study day (up to six weeks between study days)
Other Standard hematologic blood samples Differences in measures of standard hematologic biomarkers in the blood, such as platelets During the six hours of the study day (up to six weeks between study days) as well as one week after each study day
Other Standard clinical biochemical variables Differences in measurements of standard clinical biochemical biomarkers, such as alanine transaminase and creatinine During the six hours of the study day (up to six weeks between study days) as well as one week after each study day
Primary Matsuda Insulin Sensitivity Index Differences in calculated Matsuda Insulin Sensitivity Index between the two study days During two hours following a standard glucose solution (75g glucose in 250 ml of water) after the second dose of Ruminococcus or placebo has been given during the study day (second measurement up to six weeks later)
Secondary Ruminococcus Irisin-Like Peptide (RUCILP) Differences in plasma RUCILP concentration between the two study days During the six hours of the study day (up to six weeks between study days)
Secondary Peptide YY Differences in plasma Peptide YY concentration between the two study days During the six hours of the study day (up to six weeks between study days)
Secondary Glucose profile Difference in blood glucose profile during the entirety of the study day During the six hours of the study day (up to six weeks between study days)
Secondary Resting energy expenditure Difference in resting energy expenditure measured by indirect calorimetric Three times during the study day for 15 minutes
Secondary Activation of brown adipose tissue Difference in temperature measured with thermographic camera of the collar bones 15 minutes 3 times during each study day
Secondary Bone dynamics Differences in measures of biomarkers of bone turnover in blood During the six hours of the study day (up to six weeks between study days)
Secondary Gut microbiota Changes in gut microbiota composition after each intervention Samples taken prior to each visit (experimental days and follow-up visits)
Secondary Metabolome Changes is plasma metabolome after intervention During the six hours of the study day (up to six weeks between study days)
Secondary Area Under the Plasma Concentration Versus Time Curve of Gucagon-Like Peptide-1 Differences in area under the curve between the two study days During the six hours of the study day (up to six weeks between study days)
Secondary Cytokine profile Differences in the cytokine profiles during the study day During the six hours of the study day
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1